Fusion of the molecular adjuvant C3d to cleavage-independent native-like HIV-1 Env trimers improves the elicited antibody response

An effective HIV vaccine likely requires the elicitation of neutralizing antibodies (NAbs) against multiple HIV-1 clades. The recently developed cleavage-independent native flexibly linked (NFL) envelope (Env) trimers exhibit well-ordered conformation and elicit autologous tier 2 NAbs in multiple animal models. Here, we investigated whether the fusion of molecular adjuvant C3d to the Env trimers can improve B- cell germinal center (GC) formation and antibody responses. To generate Env-C3d trimers, we performed a glycine-serine- based (G4S) flexible peptide linker screening and identified a linker range that allowed native folding. A 30–60- amino- acid- long linker facilitates Env-to-C3d association and achieves the secretion of well-ordered trimers and the structural integrity and functional integrity of Env and C3d. The fusion of C3d did not dramatically affect the antigenicity of the Env trimers and enhanced the ability of the Env trimers to engage and activate B cells in vitro. In mice, the fusion of C3d enhanced germinal center formation, the magnitude of Env-specific binding antibodies, and the avidity of the antibodies in the presence of an adjuvant. The Sigma Adjuvant System (SAS) did not affect the trimer integrity in vitro but contributed to altered immunogenicity in vivo, resulting in increased tier 1 neutralization, likely by increased exposure of variable region 3 (V3). Taken together, the results indicate that the fusion of the molecular adjuvant, C3d, to the Env trimers improves antibody responses and could be useful for Env-based vaccines against HIV.

[1]  J. C. Love,et al.  Low protease activity in B cell follicles promotes retention of intact antigens after immunization , 2023, Science.

[2]  B. Pulendran,et al.  Emerging concepts in the science of vaccine adjuvants , 2021, Nature reviews. Drug discovery.

[3]  J. Mascola,et al.  Vaccination with Glycan-Modified HIV NFL Envelope Trimer-Liposomes Elicits Broadly Neutralizing Antibodies to Multiple Sites of Vulnerability , 2019, Immunity.

[4]  J. Mullikin,et al.  Antibody Lineages with Vaccine-Induced Antigen-Binding Hotspots Develop Broad HIV Neutralization , 2019, Cell.

[5]  Kôzô Inoue With Complement , 2018, Journal of Innate Immunity.

[6]  R. Wyatt,et al.  Structure-Guided Redesign Improves NFL HIV Env Trimer Integrity and Identifies an Inter-Protomer Disulfide Permitting Post-Expression Cleavage , 2018, Front. Immunol..

[7]  D. Burton,et al.  HIV-1 vaccine design through minimizing envelope metastability , 2018, Science Advances.

[8]  R. Wyatt,et al.  Cleavage-Independent HIV-1 Trimers From CHO Cell Lines Elicit Robust Autologous Tier 2 Neutralizing Antibodies , 2018, Front. Immunol..

[9]  John P. Moore,et al.  Effects of Adjuvants on HIV-1 Envelope Glycoprotein SOSIP Trimers In Vitro , 2018, Journal of Virology.

[10]  Daniel W. Kulp,et al.  Precursor Frequency and Affinity Determine B Cell Competitive Fitness in Germinal Centers, Tested with Germline‐Targeting HIV Vaccine Immunogens , 2018, Immunity.

[11]  D. Weissman,et al.  Increased surface expression of HIV-1 envelope is associated with improved antibody response in vaccinia prime/protein boost immunization , 2018, Virology.

[12]  John P. Moore,et al.  Stabilization of the gp120 V3 loop through hydrophobic interactions reduces the immunodominant V3-directed non-neutralizing response to HIV-1 envelope trimers , 2017, The Journal of Biological Chemistry.

[13]  R. Wyatt,et al.  Glutaraldehyde Cross-linking of HIV-1 Env Trimers Skews the Antibody Subclass Response in Mice , 2017, Front. Immunol..

[14]  Daniel W. Kulp,et al.  Structure-based design of native-like HIV-1 envelope trimers to silence non-neutralizing epitopes and eliminate CD4 binding , 2017, Nature Communications.

[15]  Daniel W. Kulp,et al.  Elicitation of Robust Tier 2 Neutralizing Antibody Responses in Nonhuman Primates by HIV Envelope Trimer Immunization Using Optimized Approaches , 2017, Immunity.

[16]  R. Wyatt,et al.  Covalent Linkage of HIV-1 Trimers to Synthetic Liposomes Elicits Improved B Cell and Antibody Responses , 2017, Journal of Virology.

[17]  R. Koup,et al.  Vaccine priming is restricted to draining lymph nodes and controlled by adjuvant-mediated antigen uptake , 2017, Science Translational Medicine.

[18]  John P. Moore,et al.  Reducing V3 Antigenicity and Immunogenicity on Soluble, Native-Like HIV-1 Env SOSIP Trimers , 2017, Journal of Virology.

[19]  R. Wyatt,et al.  Glycine Substitution at Helix-to-Coil Transitions Facilitates the Structural Determination of a Stabilized Subtype C HIV Envelope Glycoprotein , 2017, Immunity.

[20]  Richard T. Wyatt,et al.  Particulate Array of Well‐Ordered HIV Clade C Env Trimers Elicits Neutralizing Antibodies that Display a Unique V2 Cap Approach , 2017, Immunity.

[21]  P. Zhu,et al.  In vivo electroporation in DNA-VLP prime-boost preferentially enhances HIV-1 envelope-specific IgG2a, neutralizing antibody and CD8 T cell responses. , 2017, Vaccine.

[22]  John P. Moore,et al.  Native‐like Env trimers as a platform for HIV‐1 vaccine design , 2017, Immunological reviews.

[23]  Ian A Wilson,et al.  The HIV‐1 envelope glycoprotein structure: nailing down a moving target , 2017, Immunological reviews.

[24]  R. Wyatt,et al.  Evolution of B cell analysis and Env trimer redesign , 2017, Immunological reviews.

[25]  Rafael Fernandez-Leiro,et al.  A pipeline approach to single-particle processing in RELION , 2016, bioRxiv.

[26]  John P. Moore,et al.  Sequential and Simultaneous Immunization of Rabbits with HIV-1 Envelope Glycoprotein SOSIP.664 Trimers from Clades A, B and C , 2016, PLoS pathogens.

[27]  Bryan Briney,et al.  Holes in the Glycan Shield of the Native HIV Envelope Are a Target of Trimer-Elicited Neutralizing Antibodies. , 2016, Cell reports.

[28]  R. Wyatt,et al.  Thermostability of Well-Ordered HIV Spikes Correlates with the Elicitation of Autologous Tier 2 Neutralizing Antibodies , 2016, PLoS pathogens.

[29]  D. Burton,et al.  Uncleaved prefusion-optimized gp140 trimers derived from analysis of HIV-1 envelope metastability , 2016, Nature Communications.

[30]  R. Wyatt,et al.  High-Density Array of Well-Ordered HIV-1 Spikes on Synthetic Liposomal Nanoparticles Efficiently Activate B Cells. , 2016, Cell reports.

[31]  R. Wyatt,et al.  Structure-Guided Redesign Increases the Propensity of HIV Env To Generate Highly Stable Soluble Trimers , 2015, Journal of Virology.

[32]  J. Mascola,et al.  Immunogenicity of a Prefusion HIV-1 Envelope Trimer in Complex with a Quaternary-Structure-Specific Antibody , 2015, Journal of Virology.

[33]  John P. Moore,et al.  Immunogenicity of Stabilized HIV-1 Envelope Trimers with Reduced Exposure of Non-neutralizing Epitopes , 2015, Cell.

[34]  John P. Moore,et al.  Murine Antibody Responses to Cleaved Soluble HIV-1 Envelope Trimers Are Highly Restricted in Specificity , 2015, Journal of Virology.

[35]  G. Debnath,et al.  D-101 HIV-1 neutralizing antibodies induced by native-like envelope trimers , 2016 .

[36]  John R Mascola,et al.  Antibody responses to envelope glycoproteins in HIV-1 infection , 2015, Nature Immunology.

[37]  R. Wyatt,et al.  Cleavage-independent HIV-1 Env trimers engineered as soluble native spike mimetics for vaccine design. , 2015, Cell reports.

[38]  U. Baxa,et al.  Single-Chain Soluble BG505.SOSIP gp140 Trimers as Structural and Antigenic Mimics of Mature Closed HIV-1 Env , 2015, Journal of Virology.

[39]  R. Wyatt,et al.  Well-Ordered Trimeric HIV-1 Subtype B and C Soluble Spike Mimetics Generated by Negative Selection Display Native-like Properties , 2015, PLoS pathogens.

[40]  John P. Moore,et al.  A Next-Generation Cleaved, Soluble HIV-1 Env Trimer, BG505 SOSIP.664 gp140, Expresses Multiple Epitopes for Broadly Neutralizing but Not Non-Neutralizing Antibodies , 2013, PLoS pathogens.

[41]  T. Vedvick,et al.  Working together: interactions between vaccine antigens and adjuvants , 2013, Therapeutic advances in vaccines.

[42]  L. Stamatatos,et al.  Engineering HIV envelope protein to activate germline B cell receptors of broadly neutralizing anti-CD4 binding site antibodies , 2013, The Journal of experimental medicine.

[43]  J. Mascola,et al.  Anti-HIV B Cell Lines as Candidate Vaccine Biosensors , 2012, The Journal of Immunology.

[44]  P. Zhou,et al.  Trimeric Glycosylphosphatidylinositol-Anchored HCDR3 of Broadly Neutralizing Antibody PG16 Is a Potent HIV-1 Entry Inhibitor , 2012, Journal of Virology.

[45]  M. Carroll,et al.  Regulation of humoral immunity by complement. , 2012, Immunity.

[46]  P. Zhu,et al.  HIV-1 Virus-Like Particles Produced by Stably Transfected Drosophila S2 Cells: a Desirable Vaccine Component , 2012, Journal of Virology.

[47]  D. Isenman,et al.  A Crystal Structure of the Complex Between Human Complement Receptor 2 and Its Ligand C3d , 2011, Science.

[48]  S. Degn,et al.  Trafficking of B cell antigen in lymph nodes. , 2011, Annual review of immunology.

[49]  R. Coffman,et al.  Vaccine adjuvants: putting innate immunity to work. , 2010, Immunity.

[50]  J. Mascola,et al.  Soluble HIV-1 Env trimers in adjuvant elicit potent and diverse functional B cell responses in primates , 2010, The Journal of experimental medicine.

[51]  B. Haynes,et al.  HIV-1 Envelope Induces Memory B Cell Responses That Correlate with Plasma Antibody Levels after Envelope gp120 Protein Vaccination or HIV-1 Infection1 , 2009, The Journal of Immunology.

[52]  David N Mastronarde,et al.  Automated electron microscope tomography using robust prediction of specimen movements. , 2005, Journal of structural biology.

[53]  J. Sodroski,et al.  Characterization of antibody responses to purified HIV-1 gp120 glycoproteins fused with the molecular adjuvant C3d. , 2005, Virology.

[54]  Xiping Wei,et al.  Human Immunodeficiency Virus Type 1 env Clones from Acute and Early Subtype B Infections for Standardized Assessments of Vaccine-Elicited Neutralizing Antibodies , 2005, Journal of Virology.

[55]  J. Sodroski,et al.  Factors limiting the immunogenicity of HIV-1 gp120 envelope glycoproteins. , 2004, Virology.

[56]  D. Montefiori,et al.  Enhanced avidity maturation of antibody to human immunodeficiency virus envelope: DNA vaccination with gp120-C3d fusion proteins. , 2001, AIDS research and human retroviruses.

[57]  J. Sodroski,et al.  Characterization of Stable, Soluble Trimers Containing Complete Ectodomains of Human Immunodeficiency Virus Type 1 Envelope Glycoproteins , 2000, Journal of Virology.

[58]  J. Sodroski,et al.  Modifications That Stabilize Human Immunodeficiency Virus Envelope Glycoprotein Trimers in Solution , 2000, Journal of virology.

[59]  B. Nagar,et al.  X-ray crystal structure of C3d: a C3 fragment and ligand for complement receptor 2. , 1998, Science.

[60]  M G Rossmann,et al.  Structure of bacteriophage T4 fibritin: a segmented coiled coil and the role of the C-terminal domain. , 1997, Structure.

[61]  J. Mascola,et al.  Antibodies with specificity to native gp120 and neutralization activity against primary human immunodeficiency virus type 1 isolates elicited by immunization with oligomeric gp160 , 1997, Journal of virology.

[62]  Christopher C. Goodnow,et al.  C3d of Complement as a Molecular Adjuvant: Bridging Innate and Acquired Immunity , 1996, Science.